Edition:
United Kingdom

People: Diplomat Pharmacy Inc (DPLO.N)

DPLO.N on New York Stock Exchange

5.72USD
19 Aug 2019
Change (% chg)

-- (--)
Prev Close
$5.72
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
190,170
52-wk High
$21.48
52-wk Low
$4.17

Dreyer, David 

Mr. David C. Dreyer, CPA, is an Independent Director of Diplomat Pharmacy, Inc. Mr. Dreyer currently serves as Chief Financial Officer for Prolacta Bioscience, Inc., a privately held bioscience and high growth biopharmaceutical company focused on treating premature babies in Neonatal Intensive Care Units. Mr. Dreyer started at Prolacta in February 2017. Previously, Mr. Dreyer served as Chief Financial Officer at BIOLASE, Inc. (Nasdaq:BIOL), a medical device company that develops, manufactures, and markets innovative lasers in dentistry and medicine as well as other digital equipment, from March 2015 to January 2017. From October 2010 to March 2015, Mr. Dreyer served as Chief Financial Officer, Chief Operating Officer and Secretary of Patient Safety Technologies, which develops, markets and sells healthcare products relating to surgical safety, and is a former public reporting company and a subsidiary of Stryker Corporation (NYSE: SYK) since March 2014. Previously, Mr. Dreyer was Chief Financial Officer of Alphastaff Group, Inc., a human resource outsourcing company, from August 2009 to September 2010. From September 2004 to August 2009, Mr. Dreyer served as Chief Financial Officer and Chief Accounting Officer of AMN Healthcare Services, Inc., which provided healthcare staffing for physicians, travel nurses, and allied travel. From 1997 through 2004, Mr. Dreyer served as Chief Financial Officer and Chief Accounting Officer of Sicor, Inc., a manufacturer of complex pharmaceuticals with operations in the United States and internationally, which was acquired by Teva Pharmaceutical Limited in January 2004.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 128,263
Long-Term Incentive Plans, USD --
All Other, USD 102,917
Fiscal Year Total, USD 231,180

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --